What is the mortality rate of Haemophilus influenzae pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mortality Rate of Haemophilus influenzae Pneumonia

The mortality rate of Haemophilus influenzae pneumonia ranges from 11.5% to 33% overall, with significantly higher rates (30-47%) in bacteremic cases and those with secondary staphylococcal co-infection during influenza pandemics.

Mortality Rates by Clinical Context

General Adult Population

The mortality from H. influenzae pneumonia varies substantially based on patient characteristics and disease severity:

  • Bacteremic H. influenzae pneumonia: 33% mortality in one major series 1, though another study reported no deaths in 10 bacteremic cases 2
  • HIV-infected patients: 11.5% attributable mortality, notably not higher than the general population despite severe immunosuppression 3
  • Non-bacteremic pneumonia with non-encapsulated strains: Low mortality rate 4
  • Melanesian adults: 0% mortality (all 15 patients survived with appropriate antibiotic therapy) 5

Influenza-Related Secondary Bacterial Pneumonia

During influenza pandemics, H. influenzae represents one of the predominant secondary bacterial pathogens, with distinct mortality patterns:

  • Secondary bacterial pneumonia (general): 7-24% mortality 6
  • Secondary staphylococcal pneumonia: 47% mortality (significantly higher than non-staphylococcal at 16%) 6, 7
  • Mixed viral-bacterial pneumonia: >40% mortality, similar to primary viral pneumonia 6, 7

Historical pandemic data shows H. influenzae was a predominant pathogen in the 1918 pandemic alongside S. pneumoniae and β-hemolytic streptococci 6, 7.

Key Risk Factors Associated with Higher Mortality

The following factors substantially increase mortality risk:

  • Advanced age: Patients >50 years have higher mortality rates 1
  • Chronic comorbidities: Particularly chronic obstructive pulmonary disease (COPD), alcoholism, and chronic lung disease 1, 4, 5
  • Bacteremia: Blood culture-positive cases carry significantly higher mortality 1
  • Severe CAP requiring ICU admission: 20-50% mortality for severe CAP overall 8
  • Development of septic shock: Nearly all CAP deaths occur in patients who develop severe sepsis or septic shock 8

Clinical Presentation Patterns

Understanding presentation helps predict outcomes:

  • Radiographic patterns: Both bronchopneumonia (75%) and lobar consolidation (38%) occur, with multilobular bilateral involvement more common in bacteremic type b disease 1, 4
  • Pleural complications: Frequent occurrence of effusions and empyema, which may worsen prognosis 1
  • Age-related presentations: Bacteremic pneumonia predominates in adults ≥50 years (78.7%), while meningitis is more common in children 9

Treatment Impact on Mortality

Antibiotic choice critically affects outcomes:

  • All 5 patients who did not receive ampicillin died, whereas 16 of 19 who received ampicillin survived in one series 1
  • However, β-lactamase production has become increasingly common (50% of bacteremic isolates in some series), with ampicillin resistance reaching 85.9% in recent pediatric data 2, 10
  • Current resistance patterns show cefotaxime maintains 0% resistance, while ampicillin resistance is widespread 10

Timing of antibiotic administration is crucial: Delays in appropriate antibiotic therapy increase mortality in severe CAP, and antibiotics should be administered within 4 hours of admission 6, 7, 11.

Contemporary Trends

Recent surveillance data (2011-2015) for invasive H. influenzae serotype a shows 9:

  • 95.9% hospitalization rate
  • 47.5% ICU admission among hospitalized patients
  • 6.2% in-hospital mortality
  • 17.7% adverse outcomes at discharge, increasing to 43.9% in meningitis cases

The COVID-19 pandemic significantly altered H. influenzae epidemiology, with decreased positivity rates and changes in antimicrobial resistance patterns, though long-term implications remain unclear 10.

Critical Clinical Pitfalls

  • Do not delay antibiotics for diagnostic studies in clinically unstable patients, as delays directly increase mortality 11
  • Consider β-lactamase production: Empiric therapy must account for resistance patterns; ampicillin monotherapy is no longer reliable 2, 10
  • Recognize high-risk presentations: Multilobular involvement, bacteremia, and underlying COPD signal higher mortality risk requiring aggressive management 1, 4
  • Monitor for complications: Pleural disease develops frequently during therapy and requires surveillance 1

References

2
Research

Bacteremic Hemophilus influenzae pneumonia in the adult.

Seminars in respiratory infections, 1989

3
Research

Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000

9
Research

Clinical Characteristics and Adverse Clinical Outcomes of Invasive Haemophilus influenzae Serotype a Cases-United States, 2011-2015.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Related Questions

Does an 82-year-old woman who completed a 14-day course of amoxicillin-clavulanate for pneumonia with Haemophilus influenzae require additional antibiotics now that she is COVID-19 positive?
Is Haemophilus influenzae transmitted by airborne (respiratory droplet) spread and is it contagious?
What does a high base excess on an arterial blood gas indicate?
In a 24-year-old woman with irregular intermenstrual bleeding and spotting, what is the appropriate diagnostic work-up and initial management?
How should a transdermal fentanyl patch be converted to an intravenous fentanyl infusion in an opioid‑tolerant patient?
What is the recommended duration for switching between antidepressants, including taper and washout periods for different agents?
What is the appropriate management for a patient with a peritoneal abscess, weeping leg wounds, and an improving body rash?
Why should individuals born between 1945 and 1965 be screened for hepatitis C infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.